Navigation Links
Hyperion Therapeutics Receives Orphan Drug Designation for HPN-100 for the Treatment of Urea Cycle Disorders
Date:5/5/2009

- Company preparing to initiate phase III clinical trial -

SOUTH SAN FRANCISCO, Calif., May 5 /PRNewswire/ -- Hyperion Therapeutics, Inc. today announced that HPN-100 has received orphan product designation from the U.S. Food and Drug Administration for maintenance treatment of patients with enzymes of the urea cycle. The Company recently announced results from its phase II study and intends to initiate a phase III clinical program in this indication in the second half of 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070905/AQW076LOGO)

HPN-100 is a pre-pro-drug of phenylacetic acid which is the active moiety of BUPHENYL(R), the only therapy currently FDA-approved as adjunctive therapy for the chronic management of patients with the most prevalent urea cycle deficiencies including those related to carbamylphosphate synthetase, ornithine transcarbamylase and argininosuccinic acid synthetase. HPN-100 is dosed orally in liquid form.

"Receiving orphan drug designation for HPN-100 in the treatment of urea cycle disorders is an important milestone and provides meaningful benefits to the Company as we work to complete clinical trials for this investigational compound," commented Donald Santel, Chief Executive Officer of Hyperion Therapeutics.

"The designation of HPN-100 as an orphan drug for the treatment of urea cycle disorders recognizes the unmet need that remains in this patient population," said Cindy LeMons, Executive Director of the National Urea Cycle Disorders Foundation (NUCDF). "We are encouraged by this designation and look forward to initiation of the phase III clinical trials."

About Orphan Drug Designation

Orphan drug designation is granted by the FDA Office of Orphan Drug Products to novel drugs or biologics that treat a rare disease or condition
'/>"/>

SOURCE Hyperion Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders
2. Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders
3. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
4. Hyperion Therapeutics Announces Enrollment of First Patient in Phase 1/2 Clinical Trial of GT4P in Patients With Urea Cycle Disorders
5. Sirion Therapeutics Announces Clinical Data Presentations at the 2009 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
6. Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
7. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
8. Vantia Therapeutics Pipeline Continues to Mature
9. Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity
10. Oxygen Biotherapeutics, Inc. Receives Letter From FDA Outlining Path Forward to Resume Oxycyte Clinical Trials in TBI in U.S.A.
11. Alba Therapeutics Corporation Announces the Next Clinical Trial of Its Lead Compound, Larazotide Acetate and Promotions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 2015  Pomerantz LLP is investigating claims on behalf ... "Company") (NASDAQ: VTAE ).  Such investors are ... rswilloughby@pomlaw.com or 888-476-6529, ext. 237. ... officers and/or directors have violated Sections 10(b) and 20(a) ... On February 27, 2015, the Company announced that ...
(Date:2/27/2015)... Securities lawyers at Dunnam & Dunnam ... (NASDAQ: SLXP ) in connection with a ... are encouraged to contact attorney Hamilton Lindley by ... upon the shareholder value of the transaction. Under terms ... $158.00 per share in cash. At least one analyst ...
(Date:2/27/2015)... LONDON , February 27, 2015 ... - new study showing you trends, R&D progress, and ... medicine heading? What are the commercial prospects for ... shows you potential revenues and other trends to 2025, ... ,s report lets you assess regenerative medicine : ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vitae Pharmaceuticals, Inc. - VTAE 2Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8
... Tolerability and,Additive Antiviral Activity of HCV-796 -, EXTON, ... announced additional data from a Phase 1b study,of ... virus (HCV),polymerase inhibitor at the 42nd Annual Meeting ... Liver (EASL). This meeting is,being held in Barcelona, ...
... Data on Innovative Oncology Compounds at the,American ... PARK, Ill., April 13, 2007 /PRNewswire-FirstCall/ -- ... that target,cancer. Researchers now know that cancer ... new blood vessels to deliver oxygen,and nutrients ...
Cached Medicine Technology:ViroPharma Announces Presentation of Additional HCV-796 Data at,Meeting of The European Association for the Study of the Liver 2ViroPharma Announces Presentation of Additional HCV-796 Data at,Meeting of The European Association for the Study of the Liver 3ViroPharma Announces Presentation of Additional HCV-796 Data at,Meeting of The European Association for the Study of the Liver 4ViroPharma Announces Presentation of Additional HCV-796 Data at,Meeting of The European Association for the Study of the Liver 5ViroPharma Announces Presentation of Additional HCV-796 Data at,Meeting of The European Association for the Study of the Liver 6Abbott Researchers Focus on New Cutting-Edge Approaches in the,Fight Against Cancer 2Abbott Researchers Focus on New Cutting-Edge Approaches in the,Fight Against Cancer 3Abbott Researchers Focus on New Cutting-Edge Approaches in the,Fight Against Cancer 4
(Date:3/2/2015)... The Alliance for Bangladesh Worker Safety today announced ... serve as chief safety officer. In this role, he ... and guide remediation efforts in all factories from which ... the Alliance continues to bring world-class expertise to factory ... said Alliance Independent Chair Ellen Tauscher. “His role as ...
(Date:3/2/2015)... 02, 2015 ProvidaStaff has ... its educational healthcare division to EDU Healthcare ... services to school systems and students nationwide. , “ProvidaStaff ... school districts throughout the country,” said Angela M. Lewis, ... a better organization and the introduction of EDU Healthcare ...
(Date:3/2/2015)... 2015 Final Cut Pro X ... 2 from Pixel Film Studios. , “The TranStatic Volume 2 ... said Christina Austin, CEO of Pixel Film Studios. “TranStatic Volume ... Cut Pro X editors toolbox.” , With TranStatic Volume 2 ... media altering static scrambling effects from Pixel Film Studios. Users ...
(Date:3/1/2015)... Clearwater, Florida (PRWEB) March 02, 2015 ... market their services and manage their practices ... offer an integrated all-inclusive solution. The ... development program and a medical practice management ... success and long-term financial sustainability. A referral ...
(Date:3/1/2015)... (PRWEB) March 02, 2015 As ... web works co-founders, Michael Burns and Carita Weaver, ... addition to working with the Southlake Chamber of ... i5 web works recently launched a website for ... , A primary communications tool for Hill’s campaign, ...
Breaking Medicine News(10 mins):Health News:Alliance for Bangladesh Worker Safety Names New Chief Safety Officer 2Health News:ProvidaStaff Announces New Name Change to EDU Healthcare for Its Educational Healthcare Division 2Health News:ProvidaStaff Announces New Name Change to EDU Healthcare for Its Educational Healthcare Division 3Health News:Pixel Film Studios released the TranStatic Volume 2 plugin for Final Cut Pro X today 2Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 2Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 3Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 4Health News:Website Launched for Southlake, Texas Mayoral Candidate Laura Hill 2
... Kids(R) Day Saturday, ... April 12th, SOUTH PORTLAND, Maine, ... 17 YMCAs throughout Maine to fight,childhood obesity and improve the health of Maine ... Day on Saturday, April 12., "Healthy Kids Day is essentially an open ...
... 1, 2008 Do humans hear better than animals? ... water-based living creatures are capable of hearing some lower ... However, scientists from the Hebrew University of Jerusalem and ... the reactions of single neurons give humans the capability ...
... Agency,for International Development (USAID) highlights the success of ... partnerships,in Africa as part of two White House ... Ziemer, U.S. Malaria Coordinator, and Terri Hasdorff,USAID Director ... of the White House Office of Faith-Based and ...
... Berkeley, CA, April 1, 2008 Rap music has gone ... of substance abuse to one that often glorifies illegal drug ... the genre covering nearly two decades. The study is ... Theory, a peer reviewed scientific journal., Positive portrayals of drug ...
... Remain In Patients, DUBLIN, Ohio, April 1 ... services that improve the safety and productivity,of health ... to distribute the first system cleared by the ... detection for sponge,management during surgeries., Under the ...
... with a High ... ... Inc. (OTC Bulletin Board: MDFI), a company specializing in,portable electronic medical ... concierge medical practice,based in Jupiter, Florida, is teaming with MedeFile to ...
Cached Medicine News:Health News:Anthem Sponsors Healthy Kids Day at Maine's YMCAs 2Health News:Anthem Sponsors Healthy Kids Day at Maine's YMCAs 3Health News:Humans have more distinctive hearing than animals, Hebrew U study shows 2Health News:USAID Participates in White House Office of Faith-Based and Community Initiatives Conferences in Rwanda and Zambia 2Health News:Drug use increasingly glamorized in rap music, according to new study of 2-decade trends 2Health News:Drug use increasingly glamorized in rap music, according to new study of 2-decade trends 3Health News:Cardinal Health, ClearCount Medical Solutions Sign Primary Distribution Agreement for RFID-Enabled Sponge Counting, Detection System 2Health News:Cardinal Health, ClearCount Medical Solutions Sign Primary Distribution Agreement for RFID-Enabled Sponge Counting, Detection System 3Health News:Personal Choice Family Practice Empowers Patients With MedeFile Electronic Medical Records Management Solution 2Health News:Personal Choice Family Practice Empowers Patients With MedeFile Electronic Medical Records Management Solution 3Health News:Personal Choice Family Practice Empowers Patients With MedeFile Electronic Medical Records Management Solution 4Health News:Personal Choice Family Practice Empowers Patients With MedeFile Electronic Medical Records Management Solution 5Health News:Personal Choice Family Practice Empowers Patients With MedeFile Electronic Medical Records Management Solution 6
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: